Effect of SGLT2 Inhibitors on Anemic CKD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

NCT07063316

Chronic Kidney Disease

ACTIVE_NOT_RECRUITING

Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

NCT07302464

Sodium Glucose Co-Transporter 2 Inhibitors Estimated Glomerular Filtration Rate Diabetes +1 more

COMPLETED

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

NCT03573102

Diabetic Nephropathies

UNKNOWN PHASE4

SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

NCT07344922

Chronic Kidney Disease Anemia Cardiovascular Calcification

COMPLETED PHASE3

SGLT2-inhibitors on PC-AKI

NCT06491953

Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia in CKD Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CKD patients stage 1_4

SGLT2 inhibitor

Intervention Type DRUG

prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SGLT2 inhibitor

prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age more than 18 years
* CKD stage 1\_4
* baseline hemoglobin 8.5 to 12.9 g/dl
* stable anemia regimen for more than 8 weeks

Exclusion Criteria

* dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes